Brainstorm Cell Therapeutics reported $2.86M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Biogen BIIB:US $ 634.9M 153M
Brainstorm Cell Therapeutics BCLI:US $ 2.86M 324K
Cerulean Pharma CERU:US $ 2.59M 168.34K
Cytokinetics CYTK:US $ 33.07M 736K
Gilead Sciences GILD:US $ 1.08B 567M
Halozyme Therapeutics HALO:US $ 13.83M 60K
Idera Pharmaceuticals IDRA:US $ 2.4M 381K